Type II Diabetes Drugs Onglyza And Kombiglyze XR Increase Your Risk Of Heart Failure

Type II Diabetes Drugs Onglyza And Kombiglyze XR Increase Your Risk Of Heart Failure

The type II diabetes medications Onglyza and Kombiglyze XR have been linked to an increased risk of heart failure, and death. The pharmaceutical giants AstraZeneca and Bristol-Myers Squibb sought FDA approval of these medications in 2008. Soon after, an FDA advisory committee voted unanimously to require additional testing of the drugs to confirm cardiovascular safety. AstraZeneca and Bristol-Myers Squibb began marketing these drugs to consumers anyway. Ultimately, after a two-year long study of 16,000 individuals showed a 27% increased risk of heart failure associated with Onglyza and Kombiglyze XR the FDA Panel recommended the drugs’ manufacturers add warning labels or remove the drugs from the market. On April 5, 2016 the FDA issued the following Safety Announcement:

A U.S. Food and Drug Administration (FDA) safety review has found that type 2 diabetes medicines containing saxagliptin (the active ingredient in Onglyza and Kombiglyze XR) and alogliptin may increase the risk of heart failure…

Porter & Malouf attorneys Tim Porter and Laurel Li Harris continue to file lawsuits on behalf of consumers who suffered from heart failure after taking Onglyza and Kombiglyze XR. If you or someone you care about has been diagnosed with heart failure, or a related cardiac event after taking these drugs please contact Porter & Malouf, P.A. to submit a claim as soon as possible as your statute of limitations may be running out.

No Comments

Post A Comment